DNA Ploidy and S-phase Fraction as Predictive Factors of Response and Outcome Following Neoadjuvant Methotrexate, Vinblastine, Epirubicin and Cisplatin (M-VEC) Chemotherapy for Invasive Bladder Cancer

By Türkölmez K.   Baltaci S.   Bedük Y.   Müftüoğlu Y. Z.   Göğüş O.  

Scandinavian Journal of Urology and Nephrology, Vol. 36, Iss. 1, 2002-01 ,pp. : 46-51

Informa Healthcare

Access to resources Recommend Favorite

The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer

By Kim Philip   Kent Matthew   Zhao Philip   Sfakianos John   Bajorin Dean   Bochner Bernard   Dalbagni Guido  

World Journal of Urology, Vol. 32, Iss. 2, 2014-04 ,pp. : 453-459

Springer Publishing Company

Access to resources Recommend Favorite

Neoadjuvant chemotherapy for bladder cancer

By Black Peter   Brown Gordon   Grossman H.   Dinney Colin  

World Journal of Urology, Vol. 24, Iss. 5, 2006-11 ,pp. : 531-542

Springer Publishing Company

Access to resources Recommend Favorite

Chemotherapy for invasive bladder cancer

By Malkowicz S.B.   Vaughn D.J.  

Urology, Vol. 47, Iss. 4, 1996-04 ,pp. : 602-614

Elsevier

Access to resources Recommend Favorite

The role of rescue radical cystectomy (RCT) in a bladder preservation program based on tur plus chemotherapy for patients with invasive blaader cancer

By Solsona E.   Iborra I.   Ricos J.V.   Monros J.L.   Dumont R.   Rubio J.   Casanova J.L.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 128-128

Elsevier

Access to resources Recommend Favorite